IL96601A - Plasminogen analogues that can be activated by thrombin or factor AX - Google Patents

Plasminogen analogues that can be activated by thrombin or factor AX

Info

Publication number
IL96601A
IL96601A IL9660190A IL9660190A IL96601A IL 96601 A IL96601 A IL 96601A IL 9660190 A IL9660190 A IL 9660190A IL 9660190 A IL9660190 A IL 9660190A IL 96601 A IL96601 A IL 96601A
Authority
IL
Israel
Prior art keywords
plasminogen
gly
cleavage site
pro
cys
Prior art date
Application number
IL9660190A
Other languages
English (en)
Hebrew (he)
Other versions
IL96601A0 (en
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology filed Critical British Bio Technology
Publication of IL96601A0 publication Critical patent/IL96601A0/xx
Publication of IL96601A publication Critical patent/IL96601A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C12N2830/704—S. cerevisiae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/107—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translational read-through

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
IL9660190A 1989-12-07 1990-12-07 Plasminogen analogues that can be activated by thrombin or factor AX IL96601A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898927722A GB8927722D0 (en) 1989-12-07 1989-12-07 Proteins and nucleic acids

Publications (2)

Publication Number Publication Date
IL96601A0 IL96601A0 (en) 1991-09-16
IL96601A true IL96601A (en) 1999-05-09

Family

ID=10667597

Family Applications (2)

Application Number Title Priority Date Filing Date
IL96602A IL96602A0 (en) 1989-12-07 1990-12-07 Fusion proteins and nucleic acid coding for such proteins
IL9660190A IL96601A (en) 1989-12-07 1990-12-07 Plasminogen analogues that can be activated by thrombin or factor AX

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL96602A IL96602A0 (en) 1989-12-07 1990-12-07 Fusion proteins and nucleic acid coding for such proteins

Country Status (21)

Country Link
US (2) US5637492A (de)
EP (2) EP0504241A1 (de)
JP (2) JPH05502374A (de)
KR (2) KR920703818A (de)
AT (1) ATE155812T1 (de)
AU (3) AU644399B2 (de)
CA (2) CA2069105A1 (de)
DE (1) DE69031127T2 (de)
DK (1) DK0502968T3 (de)
ES (1) ES2106073T3 (de)
FI (2) FI105202B (de)
GB (1) GB8927722D0 (de)
GR (1) GR3024990T3 (de)
HU (1) HU211628A9 (de)
IE (2) IE904416A1 (de)
IL (2) IL96602A0 (de)
NO (2) NO922237L (de)
NZ (2) NZ236330A (de)
PT (2) PT96103B (de)
WO (2) WO1991009125A1 (de)
ZA (2) ZA909854B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22277A1 (es) * 1990-05-23 1995-01-31 Cigb Procedimiento para el aislamiento y expresion de un gen codificante para estreptoquinasa,secuencia nucleotidica obtenida,adn recombinantes y microorganismos transformados
GB9222758D0 (en) * 1992-10-29 1992-12-09 British Bio Technology Proteins and nucleic acids
GB9216558D0 (en) * 1992-08-04 1992-09-16 British Bio Technology Modified proteases
GB2286190B (en) * 1992-10-29 1996-05-01 British Biotech Pharm Thrombin activatable plasminogen derivatives
DE4323754C1 (de) * 1993-07-15 1994-12-01 Gruenenthal Gmbh Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung
AU685835B2 (en) * 1993-08-04 1998-01-29 Novartis Ag High molecular weight desulphatohirudin
ES2080657B1 (es) * 1993-09-27 1996-11-01 Britisch Bio Technology Limite Proteasas modificadas.
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
DE69535405T2 (de) * 1994-04-26 2007-11-15 Children's Medical Center Corp., Boston Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US5854049A (en) * 1995-06-09 1998-12-29 President And Fellows Of Harvard College Plasmin-resistant streptokinase
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
JP2000504941A (ja) * 1996-08-02 2000-04-25 ロシュ ダイアグノスティックス ゲーエムベーハー トロンビンによって活性化され得るプラスミノーゲンアクチベーター
GB2339430A (en) * 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
EP0947585B1 (de) 1998-03-19 2001-07-25 INSTRUMENTATION LABORATORY S.p.A. Verbesserte in vitro Verfahren, Testkits und Reagenzien zum Screening von Blutgerinnungsfehlern
WO2000010506A2 (en) 1998-08-20 2000-03-02 University Of Vermont And State Agriculture College Angiogenesis inhibitors and uses thereof
IN190822B (de) * 1998-12-24 2003-08-23 Council Scient Ind Res
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
CA2421251A1 (en) * 2000-09-05 2002-03-14 Karolinska Innovations Ab Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10108212A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE10108100A1 (de) * 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
DE10108211A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
WO2003068934A2 (en) * 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (de) 2006-06-14 2007-12-19 CSL Behring GmbH Fusionsprotein welches proteolytisch geschnitten werden kann und einen Faktor der Blutgerinnungskaskade enthält
ES2910207T3 (es) 2006-06-14 2022-05-11 Csl Behring Gmbh Proteínas de fusión escindibles proteolíticamente que comprenden un factor de coagulación de la sangre
US20100144622A1 (en) * 2006-09-29 2010-06-10 Xinli Lin Methods for production of recombinant plasminogen and plasmin polypeptides
CN1970574B (zh) * 2006-12-08 2010-08-25 中国药科大学 溶栓和抗凝双重功效融合蛋白、制备方法及其应用
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
EP2454271A4 (de) * 2009-07-15 2015-08-12 Univ California Peptide mit steuerbarer zellulärer aufnahme
ES2700230T3 (es) 2009-10-30 2019-02-14 Albumedix Ltd Variantes de albúmina
MX2013001385A (es) * 2010-08-05 2013-07-15 Council Scient Ind Res Construcciones de fusion de proteina que tienen propiedades tromboliticas y anticoagulantes.
JP6124150B2 (ja) 2011-07-29 2017-05-10 アベラス バイオサイエンシーズ，インク． 選択的な送達分子及び使用方法
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
AU2013343503B2 (en) 2012-11-08 2017-12-14 Albumedix Ltd. Albumin variants
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
MX366375B (es) 2013-01-30 2019-07-05 Avelas Biosciences Inc Moleculas de administracion selectiva y metodos de uso.
EP3318124A3 (de) 2013-02-16 2018-05-30 Albumedix A/S Pharmakokinetisches tiermodell
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
EP3337816B1 (de) 2015-08-20 2024-02-14 Albumedix Ltd Albumin-varianten und -konjugate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1897087A (en) * 1927-12-14 1933-02-14 Tamarin Bernard Jacques Vacuum cleaner cord control device
US3608333A (en) * 1968-06-20 1971-09-28 Bison Mfg Co Inc Vacuum cleaner and power unit
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
US4880776A (en) * 1983-12-24 1989-11-14 Beecham Group P.L.C. Plasmin A-chain urokinase B-chain hybrid protein
DE3410437A1 (de) * 1984-03-22 1985-09-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von proteinen
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5200340A (en) * 1987-05-22 1993-04-06 Zymogenetics, Inc. Thrombin-activated tissue plasminogen activators
EP0292009A1 (de) * 1987-05-22 1988-11-23 Zymogenetics, Inc. Fibrinolytische Proteine
EP0296413A2 (de) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrides Protein C und Verfahren zur Herstellung
EP0297882B1 (de) * 1987-07-01 1993-08-25 Beecham Group Plc Hybride Plasminogenaktivatoren
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1340802C (en) * 1987-08-15 1999-10-26 Yasuyuki Takahashi Senile amyloid precursor protein and an antibody specific for the same
US5188829A (en) * 1987-08-19 1993-02-23 Sagami Chemical Research Center Rapidly acting prourokinase
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
CA1340877C (en) * 1987-12-28 2000-01-18 Takashi Sugiyama Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
AU646633B2 (en) * 1989-02-17 1994-03-03 Codon Soluble analogs of thrombomodulin
AU647391B2 (en) * 1989-05-01 1994-03-24 University Of Notre Dame Du Lac, The Methods and materials for expression of human plasminogen in a eukaryotic cell system
US5164304A (en) * 1989-05-04 1992-11-17 Sri International Method and vectors for stabilizing hirudin and human laminin b1 expression
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
EP0561034B1 (de) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus

Also Published As

Publication number Publication date
PT96103B (pt) 1998-08-31
ES2106073T3 (es) 1997-11-01
WO1991009125A1 (en) 1991-06-27
ZA909853B (en) 1992-08-26
CA2069085C (en) 2000-02-01
GB8927722D0 (en) 1990-02-07
WO1991009118A2 (en) 1991-06-27
ZA909854B (en) 1992-08-26
NO922237D0 (no) 1992-06-05
EP0502968B1 (de) 1997-07-23
AU644399B2 (en) 1993-12-09
GR3024990T3 (en) 1998-01-30
EP0504241A1 (de) 1992-09-23
NZ236401A (en) 1992-03-26
AU6965691A (en) 1991-07-18
IE904417A1 (en) 1991-06-19
IE904416A1 (en) 1991-07-17
KR920703818A (ko) 1992-12-18
WO1991009118A3 (en) 1991-10-31
DE69031127T2 (de) 1998-02-05
PT96103A (pt) 1991-09-30
ATE155812T1 (de) 1997-08-15
IL96602A0 (en) 1992-05-25
US5637492A (en) 1997-06-10
AU643247B2 (en) 1993-11-11
PT96104A (pt) 1991-09-30
NZ236330A (en) 1993-05-26
CA2069085A1 (en) 1991-06-08
NO922238D0 (no) 1992-06-05
FI922610A (fi) 1992-06-05
AU6954091A (en) 1991-07-18
JPH05502374A (ja) 1993-04-28
DK0502968T3 (da) 1998-03-02
KR100188302B1 (ko) 1999-06-01
HU211628A9 (en) 1995-12-28
US5434073A (en) 1995-07-18
FI922609A (fi) 1992-06-05
FI105202B (fi) 2000-06-30
KR920703803A (ko) 1992-12-18
JPH05502375A (ja) 1993-04-28
IE81046B1 (en) 1999-12-01
AU4497693A (en) 1993-11-18
DE69031127D1 (de) 1997-09-04
EP0502968A1 (de) 1992-09-16
NO922238L (no) 1992-08-06
IL96601A0 (en) 1991-09-16
FI922609A0 (fi) 1992-06-05
NO922237L (no) 1992-08-06
CA2069105A1 (en) 1991-06-08
NO305562B1 (no) 1999-06-21
JP2851423B2 (ja) 1999-01-27
FI922610A0 (fi) 1992-06-05

Similar Documents

Publication Publication Date Title
EP0502968B1 (de) Aktivierbare fibrinolytische und antithrombotische proteine
JP2529816B2 (ja) 新規なヒト組織プラスミノゲン活性化因子突然変異体
JPH0322979A (ja) 新規プラスミノーゲン活性化因子
JP3189052B2 (ja) 抗血液凝固活性を有するポリペプチド
US20070287660A1 (en) Novel clot-specific steptokinase proteins possessing altered plasminogen activation-characteristics and a process for the preparation of said proteins
US5504001A (en) Hybrid plasminogen activator
EP0658206A1 (de) Inhibitorresitente serinproteasen
FI114102B (fi) Menetelmä trombiinin vaikutuksesta pilkkoutuvan plasminogeenianalogin valmistamiseksi
WO1989012681A1 (en) Tissue plasminogen activator analogues having improved activity
EP0387380A1 (de) Mutanten von Plasminogenaktivator aus Urin, ihre Herstellung und Verwendung
US5688664A (en) Thrombin activatable plasminogen analogues
CA2163925A1 (en) Chimeric proteins having fibrinolytic and thrombin-inhibiting properties
AU3064989A (en) Modified gene sequences encoding modified tpa and products therefrom
JPH04252185A (ja) アミド化繊維素溶解酵素及びその前駆体並びにその製造方法
HU217100B (hu) Eljárás új polipeptidek előállítására
HU210541A9 (hu) Zimogén- vagy fibrin-specifikus tulajdonságú, a 296-299 aminosav-tartományban helyettesített szöveti plazminogén aktivátor, ezt kódoló DNS-molekulák, vektorok és gazdasejtek
JPH06327473A (ja) 新規なｔ−ＰＡ改変体

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired